Mechanisms of checkpoint inhibition‐induced adverse events

Published on May 1, 2020in Clinical and Experimental Immunology3.532
· DOI :10.1111/CEI.13421
Pascal Urwyler1
Estimated H-index: 1
(Guy's and St Thomas' NHS Foundation Trust),
Irina Earnshaw1
Estimated H-index: 1
('KCL': King's College London)
+ 9 AuthorsSophie Papa17
Estimated H-index: 17
('KCL': King's College London)
Immune checkpoint inhibition has revolutionized the treatment of several solid cancers, most notably melanoma and non-small-cell lung cancer (NSCLC). Drugs targeting cytotoxic T lymphocyte antigen (CTLA)-4 and programmed cell death 1 (PD-1) have made their way into routine clinical use; however, this has not been without difficulties. Stimulation of the immune system to target cancer has been found to result in a reduction of self-tolerance, leading to the development of adverse effects that resemble autoimmunity. These adverse effects are erratic in their onset and severity and can theoretically affect any organ type. Several mechanisms for immune-related toxicity have been investigated over recent years; however, no consensus on the cause or prediction of toxicity has been reached. This review seeks to examine reported evidence for possible mechanisms of toxicity, methods for prediction of those at risk and a discussion of future prospects within the field.
📖 Papers frequently viewed together
110 Citations
64 Citations
107 Citations
#1Patrick Arnaud-Coffin (HCL Technologies)H-Index: 1
#2Denis Maillet (HCL Technologies)H-Index: 16
Last. Julien PéronH-Index: 18
view all 7 authors...
The advent of immune checkpoint-inhibitors (CPI) has transformed treatment for several cancer types. This review was performed to assess the rate of adverse events (AEs) associated with the use of CPI, alone or in combinations. A review of AEs reporting quality was also performed. All publications of Randomized Clinical Trials (RCTs) assessing CPI published before December 2017 were included. To investigate the quality of AEs reporting, a set of items was defined based on the 2004 CONSORT harms ...
53 CitationsSource
#1Alessio Cortellini (University of L'Aquila)H-Index: 18
#2Rita ChiariH-Index: 29
Last. Sebastiano ButiH-Index: 24
view all 35 authors...
Abstract Background Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non–small-cell lung cancer (NSCLC). Methods Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Univariate and multivariate analyses were performed to evaluate the relationships between types of irAEs (differentiated according to system/organ involved and to single-site/...
54 CitationsSource
#1Michael R Cook (Georgetown University)H-Index: 3
#2Chul Kim (Georgetown University)H-Index: 17
Importance Patients with HIV infection are at increased risk for cancer. Cancer is the leading cause of death among non–AIDS-defining illnesses in these patients. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of cancer. However, clinical trials of ICIs have historically excluded patients with HIV infection. The safety and efficacy profile of ICIs is unknown in this underrepresented population. Objective To summarize results on the safety and efficacy of ICI therapy in H...
102 CitationsSource
#1Peipei Gao (HUST: Huazhong University of Science and Technology)H-Index: 7
#2Cordelle Lazare (HUST: Huazhong University of Science and Technology)H-Index: 4
Last. Peng Wu (HUST: Huazhong University of Science and Technology)H-Index: 9
view all 14 authors...
Among all malignant tumors that threaten human health, virus-related tumors account for a large proportion. The treatment of these tumors is still an urgent problem to be resolved. The immune system is the “guard” of the human body, resisting the invasion of foreign substances such as viruses. Studies have shown that immunotherapy has clinical significance in the treatment of a variety of tumors. In particular, the emergence of immune checkpoint inhibitors (ICIs) in recent years has opened a new...
21 CitationsSource
#1Eugene Muchnik (URMC: University of Rochester Medical Center)H-Index: 1
#2Kah Poh Loh (URMC: University of Rochester Medical Center)H-Index: 20
Last. Ronald J. Maggiore (URMC: University of Rochester Medical Center)H-Index: 14
view all 7 authors...
OBJECTIVE: To evaluate the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in older patients with advanced non-small cell lung cancer (NSCLC) seen in routine clinical practice. DESIGN: Retrospective study. SETTING: Single academic institution and its affiliated centers. PARTICIPANTS: Patients 70 years or older with advanced-stage NSCLC seen between April 1, 2015, and April 1, 2017, and treated with ICIs. MEASUREMENTS: Efficacy data included overall survival (OS) and time to treatmen...
51 CitationsSource
#1Noha Abdel-Wahab (Assiut University)H-Index: 14
#2Houssein Safa (University of Texas MD Anderson Cancer Center)H-Index: 3
Last. Adi Diab (University of Texas MD Anderson Cancer Center)H-Index: 34
view all 12 authors...
Checkpoint inhibitors (CPIs) have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation (SOT) recipients have been excluded from clinical trials owing to concerns about alloimmunity, organ rejection, and immunosuppressive therapy. Thus, we conducted a retrospective study and literature review to evaluate the safety of CPIs in patients with cancer and prior SOT. Data were collected from the m...
89 CitationsSource
#2Mirjam FässlerH-Index: 4
#3David BomzeH-Index: 12
Last. Lukas FlatzH-Index: 25
view all 14 authors...
Checkpoint inhibitors have improved survival of metastatic melanoma. However, reliable biomarkers to predict response are still needed. Immunoglobulin G (IgG) antibody subclasses reflect immunocompetence in individuals and are known to be involved in essential functions in our immune system. This prospective study evaluated the association between serum IgG with its subclasses IgG1, IgG2, IgG3, and IgG4 and antitumor response according to RECIST 1.1. Serum samples from 49 patients were prospecti...
4 CitationsSource
#1Su Yin Lim (Macquarie University)H-Index: 24
#2Jenny H. Lee (Macquarie University)H-Index: 16
Last. Helen Rizos (Macquarie University)H-Index: 50
view all 13 authors...
Purpose: Combination PD-1 and CTLA-4 inhibitor therapy has dramatically improved the survival of patients with advanced melanoma but is also associated with significant immune-related toxicities. This study sought to identify circulating cytokine biomarkers of treatment response and immune-related toxicity. Experimental Design: The expression of 65 cytokines was profiled longitudinally in 98 patients with melanoma treated with PD-1 inhibitors, alone or in combination with anti-CTLA-4, and in an ...
99 CitationsSource
#1Sarah Abou Alaiwi (Harvard University)H-Index: 7
#2Dylan J. Martini (Emory University)H-Index: 11
Last. Lauren C. Harshman (Harvard University)H-Index: 27
view all 14 authors...
652Background: CPI can induce a range of irAEs with various degrees of severity. Clinical experience with retreatment following clinically significant irAEs is growing. Methods: We retrospectively ...
3 CitationsSource
#1Shaheen Khan (UTSW: University of Texas Southwestern Medical Center)H-Index: 19
#2Saad A. KhanH-Index: 12
Last. David E. Gerber (UTSW: University of Texas Southwestern Medical Center)H-Index: 44
view all 11 authors...
Up to 40% of cancer patients on immune checkpoint inhibitors develop clinically significant immune-related adverse events (irAEs). The role of host immune status and function in predisposing patients to the development of irAEs remains unknown. Sera from 65 patients receiving immune checkpoint inhibitors and 13 healthy controls were evaluated for 40 cytokines at pre-treatment, after 2–3 weeks and after 6 weeks and analysed for correlation with the development of irAEs. Of the 65 cancer patients ...
45 CitationsSource
Cited By18
#1Tzu-Fei WangH-Index: 17
#2Alok A. KhoranaH-Index: 67
Last. Marc CarrierH-Index: 60
view all 3 authors...
Thromboembolism is a common complication in patients with cancer and is associated with significant morbidity and mortality. Anticancer treatment is a known risk factor of cancer-associated thrombosis. Immune checkpoint inhibitors have become a mainstay of treatment in various cancers. Both venous and arterial thrombosis have been increasingly reported as adverse events associated with immune checkpoint inhibitors in recent studies, with a cumulative incidence of venous thrombosis to be 5–8% at ...
#1C. Granier (University of Paris)
#2A. Gey (University of Paris)H-Index: 2
Last. Eric Tartour (University of Paris)H-Index: 48
view all 6 authors...
Abstract Ageing implicates a remodeling of our immune system, which is a consequence of the physiological senescence of our cells and tissues coupled with environmental factors and chronic antigen exposure. An immune system that senesces includes more differentiated cells with accumulation of highly differentiated CD4 and CD8 T cells. The pool of naive T cells decreases with the exponential thymic involution induced by age. Differentiated T cells have similar, if not higher, functional capacitie...
1 CitationsSource
#1Alvise Berti (Mayo Clinic)H-Index: 17
#2Roberto BortolottiH-Index: 7
Last. Antonello VecciaH-Index: 14
view all 10 authors...
INTRODUCTION The introduction in clinical practice of the immune checkpoint inhibitors (ICIs) radically changed the treatment algorithm of lung cancers. To characterize the toxicity of ICIs (atezolizumab, durvalumab, nivolumab, pembrolizumab) is important for personalizing treatment. PATIENTS AND METHODS We performed a systematic review and meta-analysis of phase III randomized controlled trials assessing ICIs, from inception until April 23rd, 2020. We extracted the data from the ICI arm of each...
Immune checkpoint blockade (ICB) therapy has been considered as an effective way to boost immune cells to recognize and attack tumors. However, side effects known as immune-related adverse events (irAEs) should be carefully managed. Here, we engineer immunosuppressive nanoparticles by coating PD-L1 overexpressed mesenchymal stem cells (MSCs) plasma membrane on poly lactic-co-glycolic acid nanoparticles (MSC-PD-L1+ NPs) for managing and reducing irAEs induced by immune checkpoint inhibitors. The ...
It is 70 years since Noel Rose embarked on his pioneering studies that lead to the discovery of autoimmune thyroiditis and the elucidation of Hashimoto's thyroiditis. This short review to honour his passing focuses on the developments in our understanding of the causes and pathogenesis of HT over the last five years. Recent genetic studies have reported heritability estimates for HT and associated diseases for the first time, and emphasised the complexity of the genetic factors involved, includi...
2 CitationsSource
#1Beate Husain (FAU: University of Erlangen-Nuremberg)
#2Michael C. Kirchberger (FAU: University of Erlangen-Nuremberg)H-Index: 14
Last. Lucie Heinzerling (FAU: University of Erlangen-Nuremberg)H-Index: 35
view all 8 authors...
PURPOSE Immune checkpoint inhibitors (ICI) are highly effective in several cancer entities, but also invoke a variety of immune-related adverse events (irAE). These are mostly reversible, but can be life-threatening or even fatal. Currently, the pathogenesis is not fully understood, but crucial for effective treatment. Prediction and early detection of irAE could be facilitated and treatment optimized if relevant biomarkers and effector mechanisms were better characterized. METHODS This study in...
2 CitationsSource
#1Ke ChenH-Index: 1
#2Xiao WangH-Index: 1
Last. Zheling ChenH-Index: 1
view all 4 authors...
BACKGROUND Treatment options for advanced gastric esophageal cancer are quite limited. Chemotherapy is unavoidable at certain stages, and research on targeted therapies has mostly failed. The advent of immunotherapy has brought hope for the treatment of advanced gastric esophageal cancer. The aim of the study was to analyze the safety of anti-PD-1/PD-L1 immunotherapy and the long-term survival of patients who were diagnosed as gastric esophageal cancer and received anti-PD-1/PD-L1 immunotherapy....
4 CitationsSource
#1Josefien W. Hommes (UU: Utrecht University)H-Index: 1
#2Rik J Verheijden (UU: Utrecht University)H-Index: 2
Last. Dörte Hamann (UU: Utrecht University)H-Index: 4
view all 4 authors...
Immune checkpoint inhibitors (ICIs) have substantially improved the prognosis of patients with different types of cancer. Through blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), negative feedback mechanisms of the immune system are inhibited, potentially resulting in very durable anti-tumor responses. Despite their promise, ICIs can also elicit auto-immune toxicities. These immune-related adverse events (irAEs) can be severe and sometimes even fa...
9 CitationsSource
#1Erminia RomanoH-Index: 1
#2Jamie HoneychurchH-Index: 19
Last. Timothy M IllidgeH-Index: 56
view all 3 authors...
Radiotherapy (RT) is highly effective at directly killing tumor cells and plays an important part in cancer treatments being delivered to around 50% of all cancer patients. The additional immunomodulatory properties of RT have been investigated, and if exploited effectively, have the potential to further improve the efficacy of RT and cancer outcomes. The initial results of combining RT with immunomodulatory agents have generated promising data in pre-clinical studies, which has in turn led to a...
5 CitationsSource